{
    "clinical_study": {
        "@rank": "149821", 
        "arm_group": {
            "arm_group_label": "MK-5172+MK-8742", 
            "arm_group_type": "Experimental", 
            "description": "Participants receive MK-5172 100 mg + MK-8742 50 mg fixed-dose combination tablets, orally once daily for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of MK-5172 100 mg in\n      combination with MK-8742 50 mg in the treatment of chronic hepatitis C virus (HCV) genotype\n      1 (GT1), GT4, GT5 or GT6 infection in treatment-na\u00efve participants who are on opiate\n      substitution therapy (OST). The primary hypothesis is that the percentage of participants\n      who receive MK-5172+MK-8742 and achieve a Sustained Virologic Response 12 weeks after the\n      end of all study therapy (SVR12) will be superior to 67%."
        }, 
        "brief_title": "An Efficacy and Safety Study of MK-5172 + MK-8742 in the Treatment of Chronic Hepatitis C Virus Genotype 1, 4, 5 or 6 Infection in Treatment-Na\u00efve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented chronic HCV genotype 1 (GT1), GT4, GT5, or GT6 infection with no evidence\n             of GT2 or GT3 or non-typeable genotypes\n\n          -  On opiate substitution therapy (OST; methadone, levamethadone, buprenorphine,\n             naloxone, naltrexone) for at least 3 months prior to screening\n\n          -  Treatment na\u00efve to all HCV therapies\n\n          -  If HIV-infected, must be currently na\u00efve to treatment with any antiretroviral therapy\n             (ART) OR on a stable HIV ART for at least 8 weeks prior to study entry using a dual\n             nucleoside reverse transcriptase inhibitor (NRTI) backbone of tenofovir or abacavir\n             and either emtricitabine or lamivudine PLUS raltegravir (or dolutegravir or\n             rilpivirine)\n\n          -  If HIV-infected, cluster of differentiation 4 (CD4+) T-cell count >200 cells/mm^3 if\n             on stable ART or >500 cell/mm^3 if ART treatment na\u00efve\n\n          -  If HIV-infected, documented undetectable plasma HIV-1 ribonucleic acid (RNA) at least\n             8 weeks prior to screening if on stable ART or <50,000 copies/mL if ART treatment\n             na\u00efve\n\n        Exclusion Criteria:\n\n          -  Evidence of decompensated liver disease\n\n          -  For participants with cirrhosis, participants who are Child-Pugh Class B or C or who\n             have a Pugh-Turcotte (CPT) score >6\n\n          -  Co-infected with hepatitis B virus\n\n          -  Has cirrhosis and liver imaging with 6 months of Day 1 showing evidence of\n             hepatocellular carcinoma (HCC) or is under evaluation for HCC\n\n          -  Currently using or intends to use barbiturates during the treatment period of this\n             study\n\n          -  Any medical condition requiring or likely to require chronic systemic administration\n             of corticosteroids during the course of the trial\n\n          -  Evidence or history of chronic hepatitis not caused by HCV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105688", 
            "org_study_id": "5172-062", 
            "secondary_id": "2014-000343-32"
        }, 
        "intervention": {
            "arm_group_label": "MK-5172+MK-8742", 
            "intervention_name": "MK-5172 100 mg/MK-8742 50 mg fixed-dose combination tablets", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na\u00efve Subjects With Chronic HCV GT1, GT4, GT5, and GT6 Infection Who Are on Opiate Substitution Therapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of partcipants achieving Sustained Virologic Response 12 week after the end of all study therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Follow-up Week 12 (Up to 24 weeks)"
            }, 
            {
                "measure": "Percentage of participants experiencing adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 weeks"
            }, 
            {
                "measure": "Percentage of participants discontinuing study drug due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)", 
            "safety_issue": "No", 
            "time_frame": "Follow-up Week 24 (Up to 36 weeks)"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}